64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.

Citation

• Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., . . . Emmett, L. (2022). 64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.. Journal of Clinical Oncology, 40(16_suppl), 3092. doi:10.1200/jco.2022.40.16_suppl.3092

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.3092

Web Of Science Accession Number

Start Page

• 3092

End Page

• 3092

Volume

• 40

Issue

• 16_suppl

Abstract

UOW Authors

•   Malaroda, Alessandra

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., . . . Emmett, L. (2022). 64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.. Journal of Clinical Oncology, 40(16_suppl), 3092. doi:10.1200/jco.2022.40.16_suppl.3092

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.3092

Web Of Science Accession Number

Start Page

• 3092

End Page

• 3092

Volume

• 40

Issue

• 16_suppl